Uni Pharma Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2018
April 22, 2019 at 03:33 am
Share
Uni Pharma Co., Ltd. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced total revenue was TWD 161.743 million compared to TWD 167.867 million a year ago. Operating loss was TWD 21.307 million compared to operating Income of TWD 12.442 million a year ago. Net loss was TWD 40.354 million compared to net income of TWD 17.262 million a year ago. Basic loss per share was TWD 1.36 compared to basic earnings per share of TWD 0.65 a year ago.
UNI PHARMA CO., LTD. is a Taiwan-based company maily engaged in wholesale of diagnostdic reagents, medical equipment and medicines. The Company's main products include Onko-SureDR-70, for monitoring and marking after Colorectal cancer surgery;Cervi-M, using in detection of DNA methylation for Cervical cancer; EZ Detect, home use fecal occult blood test paper;RFA, cancer treatment medical equipment;Bain inj, a kind of morphine analgesics;Naloxone inj, antidote for morphine drugs overdose;Esmolol inj, ultrashort type B sympathetic nerve blockers;Fomepizole inj, a kind of alcoholic poisoning antidote;and Tambocor tab, a kind of arrhythmia treatment.